SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Lifecore Biomedical, Inc./DE – ‘10-Q’ for 2/26/23 – ‘EX-31.1’

On:  Friday, 6/2/23, at 4:01pm ET   ·   For:  2/26/23   ·   Accession #:  1005286-23-95   ·   File #:  0-27446

Previous ‘10-Q’:  ‘10-Q’ on 3/16/23 for 11/27/22   ·   Latest ‘10-Q’:  This Filing   ·   11 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 6/02/23  Lifecore Biomedical, Inc./DE      10-Q        2/26/23   63:8.3M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.88M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
11: R1          Cover Page                                          HTML     71K 
12: R2          Consolidated Balance Sheets                         HTML    149K 
13: R3          Consolidated Balance Sheets (Parenthetical)         HTML     36K 
14: R4          Consolidated Statements of Comprehensive (Loss)     HTML    168K 
                Income                                                           
15: R5          Consolidated Statements of Comprehensive (Loss)     HTML     21K 
                Income (Parenthetical)                                           
16: R6          Consolidated Statement of Changes in Convertible    HTML    104K 
                Preferred Stock and Stockholders? Equity                         
17: R7          Consolidated Statements of Cash Flows               HTML    126K 
18: R8          Organization, Basis of Presentation, and Summary    HTML    147K 
                of Significant Accounting Policies                               
19: R9          Convertible Preferred Stock                         HTML     31K 
20: R10         Stock-based Compensation and Stockholders' Equity   HTML     41K 
21: R11         Diluted Earnings Per Share                          HTML     42K 
22: R12         Income Taxes                                        HTML     25K 
23: R13         Debt                                                HTML     41K 
24: R14         Business Segment Reporting                          HTML    123K 
25: R15         Restructuring Costs                                 HTML     55K 
26: R16         Discontinued Operations                             HTML     75K 
27: R17         Subsequent Events                                   HTML     45K 
28: R18         Organization, Basis of Presentation, and Summary    HTML     89K 
                of Significant Accounting Policies (Policies)                    
29: R19         Organization, Basis of Presentation, and Summary    HTML    105K 
                of Significant Accounting Policies (Tables)                      
30: R20         Stock-based Compensation and Stockholders' Equity   HTML     36K 
                (Tables)                                                         
31: R21         Diluted Earnings Per Share (Tables)                 HTML     41K 
32: R22         Debt (Tables)                                       HTML     32K 
33: R23         Business Segment Reporting (Tables)                 HTML    119K 
34: R24         Restructuring Costs (Tables)                        HTML     52K 
35: R25         Discontinued Operations (Tables)                    HTML     75K 
36: R26         Organization, Basis of Presentation, and Summary    HTML    139K 
                of Significant Accounting Policies - Narrative                   
                (Details)                                                        
37: R27         Organization, Basis of Presentation, and Summary    HTML     29K 
                of Significant Accounting Policies -                             
                Reconciliation of Cash, Cash Equivalents (Details)               
38: R28         Organization, Basis of Presentation, and Summary    HTML     27K 
                of Significant Accounting Policies - Components of               
                Inventories (Details)                                            
39: R29         Organization, Basis of Presentation, and Summary    HTML     27K 
                of Significant Accounting Policies - Allowance for               
                Credit Loss Rollforward (Details)                                
40: R30         Organization, Basis of Presentation, and Summary    HTML     36K 
                of Significant Accounting Policies - Components of               
                Other Comprehensive Income (Details)                             
41: R31         Organization, Basis of Presentation, and Summary    HTML     42K 
                of Significant Accounting Policies - Fair Value of               
                Assets and Liabilities (Details)                                 
42: R32         Organization, Basis of Presentation, and Summary    HTML     38K 
                of Significant Accounting Policies -                             
                Disaggregation of Revenue (Details)                              
43: R33         Convertible Preferred Stock (Details)               HTML     66K 
44: R34         Stock-based Compensation and Stockholders' Equity   HTML     40K 
                - Narrative (Details)                                            
45: R35         Stock-based Compensation and Stockholders' Equity   HTML     32K 
                - Summary of Stock-based Compensation by Income                  
                Statement Line Item (Details)                                    
46: R36         Diluted Earnings Per Share - Diluted Earnings Per   HTML     54K 
                Share (Details)                                                  
47: R37         Income Taxes (Details)                              HTML     29K 
48: R38         Debt - Schedule of Long-term Debt (Details)         HTML     32K 
49: R39         Debt - Narrative (Details)                          HTML     88K 
50: R40         Business Segment Reporting - Narrative (Details)    HTML     36K 
51: R41         Business Segment Reporting - Sales by Geographic    HTML     40K 
                Area (Details)                                                   
52: R42         Business Segment Reporting - Operations by          HTML     74K 
                Business Segment (Details)                                       
53: R43         Restructuring Costs - Schedule of Restructuring     HTML     43K 
                Related Activities (Details)                                     
54: R44         Restructuring Costs - Narrative (Details)           HTML     21K 
55: R45         Discontinued Operations - Narrative (Details)       HTML     44K 
56: R46         Discontinued Operations - Assets and Liabilities    HTML     90K 
                (Details)                                                        
57: R47         Discontinued Operations - Income (Details)          HTML     69K 
58: R48         Subsequent Events (Details)                         HTML     89K 
61: XML         IDEA XML File -- Filing Summary                      XML    111K 
59: XML         XBRL Instance -- lfcr-20230226_htm                   XML   2.19M 
60: EXCEL       IDEA Workbook of Financial Report Info              XLSX    140K 
 7: EX-101.CAL  XBRL Calculations -- lfcr-20230226_cal               XML    215K 
 8: EX-101.DEF  XBRL Definitions -- lfcr-20230226_def                XML    617K 
 9: EX-101.LAB  XBRL Labels -- lfcr-20230226_lab                     XML   1.54M 
10: EX-101.PRE  XBRL Presentations -- lfcr-20230226_pre              XML    898K 
 6: EX-101.SCH  XBRL Schema -- lfcr-20230226                         XSD    131K 
62: JSON        XBRL Instance as JSON Data -- MetaLinks              424±   652K 
63: ZIP         XBRL Zipped Folder -- 0001005286-23-000095-xbrl      Zip    413K 


‘EX-31.1’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, James G. Hall, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Lifecore Biomedical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

(a)    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)     designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)     evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)     all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)     any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 2, 2023
 /s/ James G. Hall                                         
 James G. Hall
 President and Chief Executive Officer
(Principal Executive Officer)



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:6/2/23
For Period end:2/26/23NT 10-Q
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/09/23  Lifecore Biomedical, Inc./DE      424B3                  1:236K                                   Workiva Inc Wde… FA01/FA
 6/06/23  Lifecore Biomedical, Inc./DE      S-1/A                  2:365K                                   Workiva Inc Wde… FA01/FA


9 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/23/23  Lifecore Biomedical, Inc./DE      8-K:1,2,7,9 5/22/23   17:4.4M
 2/07/23  Lifecore Biomedical, Inc./DE      8-K:1,2     2/07/23   11:26M
 1/10/23  Lifecore Biomedical, Inc./DE      8-K:1,2,3,5 1/09/23   16:118M
11/16/22  Lifecore Biomedical, Inc./DE      8-K:5,7,9  11/14/22   13:205K
10/19/20  Lifecore Biomedical, Inc./DE      8-K:5,8,9  10/14/20    2:78K
 5/24/19  Lifecore Biomedical, Inc./DE      8-K:5,9     5/24/19    2:39K                                    Workiva Inc Wde… FA01/FA
 5/07/19  Lifecore Biomedical, Inc./DE      8-K:5,9     5/06/19    2:39K                                    Workiva Inc Wde… FA01/FA
10/16/12  Landec Corp./CA                   8-K:5,9    10/11/12    2:208K                                   RDG Filings/FA
11/07/08  Landec Corp./CA                   8-K:1,3,8,911/06/08    5:147K                                   Business Wire/FA
Top
Filing Submission 0001005286-23-000095   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 8:33:44.1pm ET